{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:16:42Z","timestamp":1784855802624,"version":"3.55.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003748","name":"Svenska S\u00e4llskapet f\u00f6r Medicinsk Forskning","doi-asserted-by":"publisher","award":["PD20-0022"],"award-info":[{"award-number":["PD20-0022"]}],"id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2021-06602"],"award-info":[{"award-number":["2021-06602"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2021-01146"],"award-info":[{"award-number":["2021-01146"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kempe Stiftelserna","award":["SMK-1859"],"award-info":[{"award-number":["SMK-1859"]}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","award":["2020-0037"],"award-info":[{"award-number":["2020-0037"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["20 0872 Pj"],"award-info":[{"award-number":["20 0872 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"G\u00f6ran Gustafsson Foundation for Research in Natural Sciences and Medicine","award":["G\u00f6ran Gustafsson Prize"],"award-info":[{"award-number":["G\u00f6ran Gustafsson Prize"]}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["MIBEst H2020-WIDESPREAD-2018-2020\/GA 857518"],"award-info":[{"award-number":["MIBEst H2020-WIDESPREAD-2018-2020\/GA 857518"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["MIBEst H2020-WIDESPREAD-2018-2020\/GA 857518"],"award-info":[{"award-number":["MIBEst H2020-WIDESPREAD-2018-2020\/GA 857518"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002301","name":"Eesti Teadusagentuur","doi-asserted-by":"publisher","award":["PRG335"],"award-info":[{"award-number":["PRG335"]}],"id":[{"id":"10.13039\/501100002301","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Antimicrob Resist"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Slow- and non-growing bacterial populations, along with intracellular pathogens, often evade standard antibacterial treatments and are linked to persistent and recurrent infections. This necessitates the development of therapies specifically targeting nonproliferating bacteria. To identify compounds active against non-growing uropathogenic\n                    <jats:italic>Escherichia coli<\/jats:italic>\n                    (UPEC) we performed a drug-repurposing screen of 6454 approved drugs and drug candidates. Using dilution-regrowth assays, we identified 39 compounds that either kill non-growing UPEC or delay its regrowth post-treatment. The hits include fluoroquinolones, macrolides, rifamycins, biguanide disinfectants, a pleuromutilin, and anti-cancer agents. Twenty-nine of the hits have not previously been recognized as active against non-growing bacteria. The hits were further tested against non-growing\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    and\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    . Ten compounds \u2013 solithromycin, rifabutin, mitomycin C, and seven fluoroquinolones\u2014have strong bactericidal activity against non-growing\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    , killing &gt;4 log\n                    <jats:sub>10<\/jats:sub>\n                    of bacteria at 2.5\u2009\u00b5M. Solithromycin, valnemulin, evofosfamide, and satraplatin are unique in their ability to selectively target non-growing bacteria, exhibiting poor efficacy against growing bacteria. Finally, 31 hit compounds inhibit the growth of intracellular\n                    <jats:italic>Shigella flexneri<\/jats:italic>\n                    in a human enterocyte infection model, indicating their ability to permeate the cytoplasm of host cells. The identified compounds hold potential for treating persistent infections, warranting further comparative studies with current standard-of-care antibiotics.\n                  <\/jats:p>","DOI":"10.1038\/s44259-025-00097-0","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T06:34:09Z","timestamp":1744353249000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Antibacterial compounds against non-growing and intracellular bacteria"],"prefix":"10.1038","volume":"3","author":[{"given":"Niilo","family":"Kaldalu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Normunds","family":"B\u0113rzi\u0146\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stina","family":"Berglund Fick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atin","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi Charlotta","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcri","family":"Aedla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariliis","family":"Hinnu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Puhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasili","family":"Hauryliuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanel","family":"Tenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"97_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cell.2020.02.056","volume":"181","author":"K Lewis","year":"2020","unstructured":"Lewis, K. The science of antibiotic discovery. Cell 181, 29\u201345 (2020).","journal-title":"Cell"},{"key":"97_CR2","doi-asserted-by":"crossref","unstructured":"Bumann, D., Fanous, J., Li, J. & Goormaghtigh, F. Antibiotic chemotherapy against heterogeneous pathogen populations in complex host tissues. F1000Research 8, 1\u20137 (2019).","DOI":"10.12688\/f1000research.19441.1"},{"key":"97_CR3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41579-019-0196-3","volume":"17","author":"NQ Balaban","year":"2019","unstructured":"Balaban, N. Q. et al. Definitions and guidelines for research on antibiotic persistence. Nat. Rev. Microbiol. 17, 441\u2013448 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"97_CR4","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1126\/science.aaj2191","volume":"355","author":"I Levin-Reisman","year":"2017","unstructured":"Levin-Reisman, I. et al. Antibiotic tolerance facilitates the evolution of resistance. Science 355, 826\u2013830 (2017).","journal-title":"Science"},{"key":"97_CR5","doi-asserted-by":"publisher","first-page":"14734","DOI":"10.1073\/pnas.1906169116","volume":"116","author":"I Levin-Reisman","year":"2019","unstructured":"Levin-Reisman, I., Brauner, A., Ronin, I. & Balaban, N. Q. Epistasis between antibiotic tolerance, persistence, and resistance mutations. Proc. Natl Acad. Sci. USA. 116, 14734\u201314739 (2019).","journal-title":"Proc. Natl Acad. Sci. USA."},{"key":"97_CR6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1146\/annurev.micro.112408.134306","volume":"64","author":"K Lewis","year":"2010","unstructured":"Lewis, K. Persister cells. Annu. Rev. Microbiol. 64, 357\u2013372 (2010).","journal-title":"Annu. Rev. Microbiol."},{"key":"97_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/femsre\/fux001","volume":"41","author":"B van den Bergh","year":"2017","unstructured":"van den Bergh, B., Fauvart, M. & Michiels, J. Formation, physiology, ecology, evolution and clinical importance of bacterial persisters. FEMS Microbiol. Rev. 41, 219\u2013251 (2017).","journal-title":"FEMS Microbiol. Rev."},{"key":"97_CR8","doi-asserted-by":"publisher","first-page":"e00070","DOI":"10.1128\/MMBR.00070-20","volume":"84","author":"N Kaldalu","year":"2020","unstructured":"Kaldalu, N. et al. In vitro studies of persister cells. Microbiol. Mol. Biol. Rev. 84, e00070\u201320 (2020).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"97_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1146\/annurev-micro-020518-115650","volume":"73","author":"B Gollan","year":"2019","unstructured":"Gollan, B., Grabe, G., Michaux, C. & Helaine, S. Bacterial persisters and infection: past, present, and progressing. Annu. Rev. Microbiol. 73, 359\u2013385 (2019).","journal-title":"Annu. Rev. Microbiol."},{"key":"97_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrmicro.2017.42","volume":"15","author":"RA Fisher","year":"2017","unstructured":"Fisher, R. A., Gollan, B. & Helaine, S. Persistent bacterial infections and persister cells. Nat. Rev. Microbiol. 15, 453\u2013464 (2017).","journal-title":"Nat. Rev. Microbiol."},{"key":"97_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0891-5520(03)00066-7","volume":"17","author":"S Carryn","year":"2003","unstructured":"Carryn, S. et al. Intracellular pharmacodynamics of antibiotics. Infect. Dis. Clin. North Am. 17, 615\u2013634 (2003).","journal-title":"Infect. Dis. Clin. North Am."},{"key":"97_CR12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nrmicro955","volume":"2","author":"DM Monack","year":"2004","unstructured":"Monack, D. M., Mueller, A. & Falkow, S. Persistent bacterial infections: the interface of the pathogen and the host immune system. Nat. Rev. Microbiol. 2, 747\u2013765 (2004).","journal-title":"Nat. Rev. Microbiol."},{"key":"97_CR13","doi-asserted-by":"publisher","first-page":"1141868","DOI":"10.3389\/fcimb.2023.1141868","volume":"13","author":"N Personnic","year":"2023","unstructured":"Personnic, N., Doublet, P. & Jarraud, S. Intracellular persister: a stealth agent recalcitrant to antibiotics. Front. Cell. Infect. Microbiol. 13, 1141868 (2023).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"97_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/femsre\/fux010","volume":"41","author":"CW Hall","year":"2017","unstructured":"Hall, C. W. & Mah, T. F. Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria. FEMS Microbiol. Rev. 41, 276\u2013301 (2017).","journal-title":"FEMS Microbiol. Rev."},{"key":"97_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2180-12-259","volume":"12","author":"R Hazan","year":"2012","unstructured":"Hazan, R., Que, Y. A., Maura, D. & Rahme, L. G. A method for high throughput determination of viable bacteria cell counts in 96-well plates. BMC Microbiol. 12, 1\u20137 (2012).","journal-title":"BMC Microbiol."},{"key":"97_CR16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1047-2797(00)00072-7","volume":"10","author":"B Foxman","year":"2000","unstructured":"Foxman, B., Barlow, R., D\u2019Arcy, H., Gillespie, B. & Sobel, J. D. Urinary tract infection: self-reported incidence and associated costs. Ann. Epidemiol. 10, 509\u2013515 (2000).","journal-title":"Ann. Epidemiol."},{"key":"97_CR17","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3389\/fmicb.2017.01566","volume":"8","author":"ME Terlizzi","year":"2017","unstructured":"Terlizzi, M. E., Gribaudo, G. & Maffei, M. E. UroPathogenic Escherichia coli (UPEC) infections: virulence factors, bladder responses, antibiotic, and non-antibiotic antimicrobial strategies. Front. Microbiol. 8, 1566 (2017).","journal-title":"Front. Microbiol."},{"key":"97_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jinf.2017.11.001","volume":"76","author":"S Karve","year":"2018","unstructured":"Karve, S. et al. The impact of initial antibiotic treatment failure: real-world insights in patients with complicated urinary tract infection. J. Infect. 76, 121\u2013131 (2018).","journal-title":"J. Infect."},{"key":"97_CR19","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/jac\/48.6.895","volume":"48","author":"RA Lawrenson","year":"2001","unstructured":"Lawrenson, R. A. & Logie, J. W. Antibiotic failure in the treatment of urinary tract infections in young women. J. Antimicrob. Chemother. 48, 895\u2013901 (2001).","journal-title":"J. Antimicrob. Chemother."},{"key":"97_CR20","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.imbio.2011.05.011","volume":"216","author":"NJ Bokil","year":"2011","unstructured":"Bokil, N. J. et al. Intramacrophage survival of uropathogenic Escherichia coli: differences between diverse clinical isolates and between mouse and human macrophages. Immunobiology 216, 1164\u20131171 (2011).","journal-title":"Immunobiology"},{"key":"97_CR21","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/j.1574-6976.2012.00339.x","volume":"36","author":"TJ Hannan","year":"2012","unstructured":"Hannan, T. J. et al. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol. Rev. 36, 616\u2013648 (2012).","journal-title":"FEMS Microbiol. Rev."},{"key":"97_CR22","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/j.1462-5822.2006.00691.x","volume":"8","author":"DS Eto","year":"2006","unstructured":"Eto, D. S., Sundsbak, J. L. & Mulvey, M. A. Actin-gated intracellular growth and resurgence of uropathogenic Escherichia coli. Cell. Microbiol. 8, 704\u2013717 (2006).","journal-title":"Cell. Microbiol."},{"key":"97_CR23","doi-asserted-by":"publisher","first-page":"e1006238","DOI":"10.1371\/journal.ppat.1006238","volume":"13","author":"NM Gilbert","year":"2017","unstructured":"Gilbert, N. M., O\u2019Brien, V. P. & Lewis, A. L. Transient microbiota exposures activate dormant Escherichia coli infection in the bladder and drive severe outcomes of recurrent disease. PLOS Pathog. 13, e1006238 (2017).","journal-title":"PLOS Pathog."},{"key":"97_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.21037\/atm.2016.12.73","volume":"5","author":"HL Schreiber","year":"2017","unstructured":"Schreiber, H. L., Spaulding, C. N., Dodson, K. W., Livny, J. & Hultgren, S. J. One size doesn\u2019t fit all:unraveling the diversity of factors and interactions that drive E. coli urovirulence. Ann. Transl. Med. 5, 28 (2017).","journal-title":"Ann. Transl. Med."},{"key":"97_CR25","doi-asserted-by":"publisher","first-page":"49804","DOI":"10.1074\/jbc.M404299200","volume":"279","author":"BK Coombes","year":"2004","unstructured":"Coombes, B. K., Brown, N. F., Valdez, Y., Brumell, J. H. & Finlay, B. B. Expression and secretion of Salmonella pathogenicity island-2 virulence genes in response to acidification exhibit differential requirements of a functional type III secretion apparatus and SsaL. J. Biol. Chem. 279, 49804\u201349815 (2004).","journal-title":"J. Biol. Chem."},{"key":"97_CR26","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.2217\/fmb.10.125","volume":"5","author":"N H\u00f8iby","year":"2010","unstructured":"H\u00f8iby, N., Ciofu, O. & Bjarnsholt, T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol. 5, 1663\u20131674 (2010).","journal-title":"Future Microbiol."},{"key":"97_CR27","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ijantimicag.2009.12.011","volume":"35","author":"N H\u00f8iby","year":"2010","unstructured":"H\u00f8iby, N., Bjarnsholt, T., Givskov, M., Molin, S. & Ciofu, O. Antibiotic resistance of bacterial biofilms. Int. J. Antimicrob. Agents 35, 322\u2013332 (2010).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"97_CR28","doi-asserted-by":"publisher","unstructured":"Schnupf, P. & Sansonetti, P. J. Shigella pathogenesis: new insights through advanced methodologies. Microbiol. Spectr. 7, https:\/\/doi.org\/10.1128\/microbiolspec.bai-0023-2019 (2019).","DOI":"10.1128\/microbiolspec.bai-0023-2019"},{"key":"97_CR29","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-023-00906-1","volume":"21","author":"S Baker","year":"2023","unstructured":"Baker, S. & Scott, T. A. Antimicrobial-resistant Shigella: where do we go next? Nat. Rev. Microbiol. 21, 409\u2013410 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"97_CR30","unstructured":"WHO. WHO Bacterial Priority Pathogens List, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. 72 (2024)."},{"key":"97_CR31","doi-asserted-by":"publisher","first-page":"17020","DOI":"10.1073\/pnas.252529799","volume":"99","author":"RA Welch","year":"2002","unstructured":"Welch, R. A. et al. Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli. Proc. Natl. Acad. Sci. USA 99, 17020\u201317024 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"97_CR32","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.1128\/JB.00085-11","volume":"193","author":"H Luidalepp","year":"2011","unstructured":"Luidalepp, H., J\u00f5ers, A., Kaldalu, N. & Tenson, T. Age of inoculum strongly influences persister frequency and can mask effects of mutations implicated in altered persistence. J. Bacteriol. 193, 3598\u20133605 (2011).","journal-title":"J. Bacteriol."},{"key":"97_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0378-1097(03)00856-5","volume":"230","author":"I Keren","year":"2004","unstructured":"Keren, I., Kaldalu, N., Spoering, A., Wang, Y. & Lewis, K. Persister cells and tolerance to antimicrobials. FEMS Microbiol. Lett. 230, 13\u201318 (2004).","journal-title":"FEMS Microbiol. Lett."},{"key":"97_CR34","first-page":"179","volume":"4","author":"H Niu","year":"2015","unstructured":"Niu, H. et al. Identification of anti-persister activity against uropathogenic Escherichia coli from a Clinical Drug Library. Antibiotics (Basel, Switzerland) 4, 179\u2013187 (2015).","journal-title":"Antibiotics (Basel, Switzerland)"},{"key":"97_CR35","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1128\/AAC.00886-10","volume":"55","author":"A Dalhoff","year":"2011","unstructured":"Dalhoff, A., Stubbings, W. & Schubert, S. Comparative in vitro activities of the novel antibacterial finafloxacin against selected Gram-positive and Gram-negative bacteria tested in Mueller-Hinton broth and synthetic urine. Antimicrob. Agents Chemother. 55, 1814\u20131818 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"97_CR36","doi-asserted-by":"publisher","first-page":"e0146821","DOI":"10.1128\/AAC.01468-21","volume":"65","author":"I Kerkez","year":"2021","unstructured":"Kerkez, I., Tulkens, P. M., Tenson, T., van Bambeke, F. & Putrin\u0161, M. Uropathogenic Escherichia coli shows antibiotic tolerance and growth heterogeneity in an in vitro model of intracellularinfection. Antimicrob. Agents Chemother. 65, e0146821 (2021).","journal-title":"Antimicrob. Agents Chemother"},{"key":"97_CR37","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1128\/AAC.35.9.1824","volume":"35","author":"RHK Eng","year":"1991","unstructured":"Eng, R. H. K., Padberg, F. T., Smith, S. M., Tan, E. N. & Cherubin, C. E. Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria. Antimicrob. Agents Chemother. 35, 1824\u20131828 (1991).","journal-title":"Antimicrob. Agents Chemother."},{"key":"97_CR38","doi-asserted-by":"publisher","first-page":"001856","DOI":"10.1099\/jmm.0.001856","volume":"73","author":"ME Petersen","year":"2024","unstructured":"Petersen, M. E. et al. A high-throughput assay identifies molecules with antimicrobial activity against persister cells. J. Med. Microbiol. 73, 001856 (2024).","journal-title":"J. Med. Microbiol."},{"key":"97_CR39","doi-asserted-by":"crossref","unstructured":"Niu, H. et al. A clinical drug library screen identifies tosufloxacin as being highly active against Staphylococcus aureus persisters. Antibiotics 4, 329 (2015).","DOI":"10.3390\/antibiotics4030329"},{"key":"97_CR40","doi-asserted-by":"publisher","first-page":"e01746-18","DOI":"10.1128\/AAC.01746-18","volume":"63","author":"W Zimmerli","year":"2019","unstructured":"Zimmerli, W. & Sendi, P. Role of rifampin against staphylococcal biofilm infections in vitro, in animal models, and in orthopedic-device-related infections. Antimicrob. Agents Chemother. 63, e01746-18 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"97_CR41","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/infdis\/162.1.96","volume":"162","author":"AF Widmer","year":"1990","unstructured":"Widmer, A. F., Frei, R., Rajacic, Z. & Zimmerli, W. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J. Infect. Dis. 162, 96\u2013102 (1990).","journal-title":"J. Infect. Dis."},{"key":"97_CR42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/00001813-199010000-00002","volume":"1","author":"J Verweij","year":"1990","unstructured":"Verweij, J. & Pinedo, H. M. Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs 1, 5\u201313 (1990).","journal-title":"Anticancer Drugs"},{"key":"97_CR43","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.critrevonc.2012.12.003","volume":"87","author":"M Froudarakis","year":"2013","unstructured":"Froudarakis, M. et al. Revisiting bleomycin from pathophysiology to safe clinical use. Crit. Rev. Oncol. Hematol. 87, 90\u2013100 (2013).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"97_CR44","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1517\/17425255.2012.636352","volume":"8","author":"G Doshi","year":"2012","unstructured":"Doshi, G., Sonpavde, G. & Sternberg, C. N. Clinical and pharmacokinetic evaluation of satraplatin. Expert Opin. Drug Metab. Toxicol. 8, 103\u2013111 (2012).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"97_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-81841-0","volume":"11","author":"AJ Brenner","year":"2021","unstructured":"Brenner, A. J. et al. Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma. Sci. Rep. 11, 1\u20136 (2021).","journal-title":"Sci. Rep."},{"key":"97_CR46","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.bcp.2018.07.030","volume":"155","author":"J Portugal","year":"2018","unstructured":"Portugal, J. Challenging transcription by DNA-binding antitumor drugs. Biochem. Pharmacol. 155, 336\u2013345 (2018).","journal-title":"Biochem. Pharmacol."},{"key":"97_CR47","doi-asserted-by":"publisher","first-page":"9265","DOI":"10.1158\/0008-5472.CAN-10-1530","volume":"70","author":"V Kapuria","year":"2010","unstructured":"Kapuria, V. et al. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res. 70, 9265\u20139276 (2010).","journal-title":"Cancer Res."},{"key":"97_CR48","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1039\/C9CC09204H","volume":"56","author":"KM Lee","year":"2020","unstructured":"Lee, K. M., Le, P., Sieber, S. A. & Hacker, S. M. Degrasyn exhibits antibiotic activity against multi-resistant Staphylococcus aureus by modifying several essential cysteines. Chem. Commun. (Camb). 56, 2929\u20132932 (2020).","journal-title":"Chem. Commun. (Camb)."},{"key":"97_CR49","doi-asserted-by":"publisher","first-page":"948","DOI":"10.15252\/msb.20177723","volume":"13","author":"JK Srimani","year":"2017","unstructured":"Srimani, J. K., Huang, S., Lopatkin, A. J. & You, L. Drug detoxification dynamics explain the postantibiotic effect. Mol. Syst. Biol. 13, 948\u2013948 (2017).","journal-title":"Mol. Syst. Biol."},{"key":"97_CR50","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/jac\/dkh130","volume":"53","author":"A Athamna","year":"2004","unstructured":"Athamna, A., Athamna, M., Medlej, B., Bast, D. J. & Rubinstein, E. In vitro post-antibiotic effect of fluoroquinolones, macrolides, beta-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin\/dalfopristin and rifampicin on Bacillus anthracis. J. Antimicrob. Chemother. 53, 609\u2013615 (2004).","journal-title":"J. Antimicrob. Chemother."},{"key":"97_CR51","unstructured":"Babjuk, M. et al. EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. European Urology vol. 31 https:\/\/uroweb.org\/guidelines\/urological-infections (2022)."},{"key":"97_CR52","unstructured":"Chao, Y.-S. & Farrah, K. Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines. (2019)."},{"key":"97_CR53","doi-asserted-by":"publisher","unstructured":"Zheng, E. J. et al. Discovery of antibiotics that selectively kill metabolically dormant bacteria. Cell Chem. Biol. https:\/\/doi.org\/10.1016\/J.CHEMBIOL.2023.10.026 (2023).","DOI":"10.1016\/J.CHEMBIOL.2023.10.026"},{"key":"97_CR54","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nrmicro1445","volume":"4","author":"BR Levin","year":"2006","unstructured":"Levin, B. R. & Rozen, D. E. Non-inherited antibiotic resistance. Nat. Rev. Microbiol. 4, 556\u2013562 (2006).","journal-title":"Nat. Rev. Microbiol."},{"key":"97_CR55","doi-asserted-by":"publisher","first-page":"fnx254","DOI":"10.1093\/femsle\/fnx254","volume":"365","author":"GV Smirnova","year":"2018","unstructured":"Smirnova, G. V. & Oktyabrsky, O. N. Relationship between Escherichia coli growth rate and bacterial susceptibility to ciprofloxacin. FEMS Microbiol. Lett. 365, fnx254 (2018).","journal-title":"FEMS Microbiol. Lett."},{"key":"97_CR56","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1128\/AAC.30.4.521","volume":"30","author":"E Tuomanen","year":"1986","unstructured":"Tuomanen, E., Durack, D. T. & Tomasz, A. Antibiotic tolerance among clinical isolates of bacteria. Antimicrob. Agents Chemother. 30, 521\u2013527 (1986).","journal-title":"Antimicrob. Agents Chemother."},{"key":"97_CR57","doi-asserted-by":"publisher","first-page":"e74062","DOI":"10.7554\/eLife.74062","volume":"11","author":"U \u0141api\u0144ska","year":"2022","unstructured":"\u0141api\u0144ska, U. et al. Fast bacterial growth reduces antibiotic accumulation and efficacy. Elife 11, e74062 (2022).","journal-title":"Elife"},{"key":"97_CR58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejps.2018.09.008","volume":"125","author":"JW Mouton","year":"2018","unstructured":"Mouton, J. W. Soup with or without meatballs: impact of nutritional factors on the MIC, kill-rates and growth-rates. Eur. J. Pharm. Sci. 125, 23\u201327 (2018).","journal-title":"Eur. J. Pharm. Sci."},{"key":"97_CR59","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1242\/jcs.107.1.213","volume":"107","author":"I Chantret","year":"1994","unstructured":"Chantret, I. et al. Differential expression of sucrase-isomaltase in clones isolated from early and late passages of the cell line caco-2: evidence for glucose-dependent negative regulation. J. Cell Sci. 107, 213\u2013225 (1994).","journal-title":"J. Cell Sci."},{"key":"97_CR60","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/em.22267","volume":"60","author":"KH Maslowska","year":"2019","unstructured":"Maslowska, K. H., Makiela-Dzbenska, K. & Fijalkowska, I. J. The SOS system: a complex and tightly regulated response to DNA damage. Environ. Mol. Mutagen. 60, 368 (2019).","journal-title":"Environ. Mol. Mutagen."},{"key":"97_CR61","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1128\/AEM.71.5.2338-2346.2005","volume":"71","author":"A Norman","year":"2005","unstructured":"Norman, A., Hansen, L. H. & S\u00f8rensen, S. J. Construction of a ColD cda promoter-based SOS-green fluorescent protein whole-cell biosensor with higher sensitivity toward genotoxic compounds than constructs based on recA, umuDC, or sulA promoters. Appl. Environ. Microbiol. 71, 2338\u20132346 (2005).","journal-title":"Appl. Environ. Microbiol."},{"key":"97_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2164-9-488","volume":"9","author":"T Hulsen","year":"2008","unstructured":"Hulsen, T., de Vlieg, J. & Alkema, W. BioVenn\u2014A web application for the comparison and visualization of biological lists using area-proportional Venn diagrams. BMC Genomics 9, 1\u20136 (2008).","journal-title":"BMC Genomics"},{"key":"97_CR63","doi-asserted-by":"publisher","first-page":"6976","DOI":"10.1093\/nar\/gkq576","volume":"38","author":"MW Weng","year":"2010","unstructured":"Weng, M. W. et al. Repair of mitomycin C mono- and interstrand cross-linked DNA adducts by UvrABC: a new model. Nucleic Acids Res 38, 6976\u20136984 (2010).","journal-title":"Nucleic Acids Res"},{"key":"97_CR64","doi-asserted-by":"publisher","first-page":"eaav9462","DOI":"10.1126\/sciadv.aav9462","volume":"5","author":"F Goormaghtigh","year":"2019","unstructured":"Goormaghtigh, F. & Van Melderen, L. Single-cell imaging and characterization of Escherichia coli persister cells to ofloxacin in exponential cultures. Sci. Adv. 5, eaav9462 (2019).","journal-title":"Sci. Adv."},{"key":"97_CR65","doi-asserted-by":"publisher","first-page":"110427","DOI":"10.1016\/j.celrep.2022.110427","volume":"38","author":"D Wilmaerts","year":"2022","unstructured":"Wilmaerts, D., Focant, C., Matthay, P. & Michiels, J. Transcription-coupled DNA repair underlies variation in persister awakening and the emergence of resistance. Cell Rep. 38, 110427 (2022).","journal-title":"Cell Rep."},{"key":"97_CR66","doi-asserted-by":"publisher","unstructured":"V\u00f6lzing, K. G. & Brynildsen, M. P. Stationary-phase persisters to ofloxacin sustain DNA damage and require repair systems only during recovery. https:\/\/doi.org\/10.1128\/mBio.00731-15 (2015).","DOI":"10.1128\/mBio.00731-15"},{"key":"97_CR67","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nature25979","volume":"555","author":"L Maier","year":"2018","unstructured":"Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623\u2013628 (2018).","journal-title":"Nature"},{"key":"97_CR68","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1128\/CMR.12.1.147","volume":"12","author":"G Mcdonnell","year":"1999","unstructured":"Mcdonnell, G. & Russell, A. D. Antiseptics and disinfectants: activity, action, and resistance. Clin. Microbiol. Rev. 12, 147\u2013179 (1999).","journal-title":"Clin. Microbiol. Rev."},{"key":"97_CR69","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","volume":"2","author":"H Pajouhesh","year":"2005","unstructured":"Pajouhesh, H. & Lenz, G. R. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2, 541 (2005).","journal-title":"NeuroRx"},{"key":"97_CR70","doi-asserted-by":"publisher","first-page":"13673","DOI":"10.1073\/pnas.1717168115","volume":"114","author":"MS Svetlov","year":"2017","unstructured":"Svetlov, M. S., V\u00e1zquez-Laslop, N. & Mankin, A. S. Kinetics of drug-ribosome interactions defines the cidality of macrolide antibiotics. Proc. Natl Acad. Sci. USA 114, 13673\u201313678 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"97_CR71","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nrmicro2474","volume":"9","author":"JG Hurdle","year":"2011","unstructured":"Hurdle, J. G., O\u2019Neill, A. J., Chopra, I. & Lee, R. E. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat. Rev. Microbiol. 9, 62\u201375 (2011).","journal-title":"Nat. Rev. Microbiol."},{"key":"97_CR72","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3390\/pharmaceutics15030804","volume":"15","author":"A Rusu","year":"2023","unstructured":"Rusu, A., Munteanu, A. C., Arb\u0103na\u0219i, E. M. & Uivarosi, V. Overview of side-effects of antibacterial fluoroquinolones: new drugs versus old drugs, a step forward in the safety profile? Pharmaceutics 15, 804 (2023).","journal-title":"Pharmaceutics"},{"issue":"Suppl 1","key":"97_CR73","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/jac\/dkg209","volume":"51","author":"P Ball","year":"2003","unstructured":"Ball, P. Adverse drug reactions: implications for the development of fluoroquinolones. J. Antimicrob. Chemother. 51(Suppl 1), 21\u201327 (2003).","journal-title":"J. Antimicrob. Chemother."},{"key":"97_CR74","doi-asserted-by":"publisher","first-page":"OED.S7383","DOI":"10.4137\/OED.S7383","volume":"4","author":"C Schultz","year":"2012","unstructured":"Schultz, C. Gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis: safety, efficacy and patient perspective. Ophthalmol. Eye Dis. 4, OED.S7383 (2012).","journal-title":"Ophthalmol. Eye Dis."},{"key":"97_CR75","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1111\/1462-2920.12873","volume":"17","author":"BW Kwan","year":"2015","unstructured":"Kwan, B. W., Chowdhury, N. & Wood, T. K. Combatting bacterial infections by killing persister cells with mitomycin C. Environ. Microbiol. 17, 4406\u20134414 (2015).","journal-title":"Environ. Microbiol."},{"key":"97_CR76","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ijantimicag.2016.08.022","volume":"49","author":"MY Cruz-Mu\u00f1iz","year":"2017","unstructured":"Cruz-Mu\u00f1iz, M. Y. et al. Repurposing the anticancer drug mitomycin C for the treatment of persistent Acinetobacter baumannii infections. Int. J. Antimicrob. Agents 49, 88\u201392 (2017).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"97_CR77","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3390\/antibiotics13090815","volume":"13","author":"A Carocci","year":"2024","unstructured":"Carocci, A. et al. Mitomycin C as an anti-persister strategy against Klebsiella pneumoniae: toxicity and synergy studies. Antibiotics 13, 815 (2024).","journal-title":"Antibiotics"},{"key":"97_CR78","doi-asserted-by":"publisher","first-page":"e0090021","DOI":"10.1128\/AAC.00900-21","volume":"65","author":"O Pacios","year":"2021","unstructured":"Pacios, O. et al. Enhanced antibacterial activity of repurposed mitomycin C and imipenem incombination with the lytic phage vB_KpnMVAC13 against clinical isolates of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 65, e0090021 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"97_CR79","first-page":"177","volume":"13","author":"E Svedholm","year":"2024","unstructured":"Svedholm, E., Bruce, B., Parcell, B. J. & Coote, P. J. Repurposing mitomycin C in combination with pentamidine or gentamicin to treat infections with multi-drug-resistant (MDR) Pseudomonas aeruginosa. Antibiotics (Basel, Switzerland) 13, 177 (2024).","journal-title":"Antibiotics (Basel, Switzerland)"},{"key":"97_CR80","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41557-019-0378-7","volume":"12","author":"P Le","year":"2020","unstructured":"Le, P. et al. Repurposing human kinase inhibitors to create an antibiotic active against drug-resistant Staphylococcus aureus, persisters and biofilms. Nat. Chem. 12, 145\u2013158 (2020).","journal-title":"Nat. Chem."},{"key":"97_CR81","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/jac\/dkm421","volume":"61","author":"YS Park","year":"2008","unstructured":"Park, Y. S., Shin, W. S. & Kim, S. K. In vitro and in vivo activities of echinomycin against clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 61, 163\u2013168 (2008).","journal-title":"J. Antimicrob. Chemother."},{"key":"97_CR82","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1126\/science.aav4474","volume":"366","author":"M Russo","year":"2019","unstructured":"Russo, M. et al. Adaptive mutability of colorectal cancers in response to targeted therapies. Science 366, 1473\u20131480 (2019).","journal-title":"Science"},{"key":"97_CR83","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/10409230701648502","volume":"42","author":"RS Galhardo","year":"2007","unstructured":"Galhardo, R. S., Hastings, P. J. & Rosenberg, S. M. Mutation as a stress response and the regulation of evolvability. Crit. Rev. Biochem. Mol. Biol. 42, 399\u2013435 (2007).","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"97_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms2607","volume":"4","author":"A Gutierrez","year":"2013","unstructured":"Gutierrez, A. et al. \u03b2-lactam antibiotics promote bacterial mutagenesis via an RpoS-mediated reduction in replication fidelity. Nat. Commun. 4, 1\u20139 (2013).","journal-title":"Nat. Commun."},{"key":"97_CR85","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/978-1-62703-764-8_8","volume":"1116","author":"J Quan","year":"2014","unstructured":"Quan, J. & Tian, J. Circular polymerase extension cloning. Methods Mol. Biol. 1116, 103\u2013117 (2014).","journal-title":"Methods Mol. Biol."},{"key":"97_CR86","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/pharmaceutics11090487","volume":"11","author":"L Preem","year":"2019","unstructured":"Preem, L. et al. Monitoring of antimicrobial drug chloramphenicol release from electrospun nano- and microfiber mats using UV imaging and bacterial bioreporters. Pharmaceutics 11, 487 (2019).","journal-title":"Pharmaceutics"},{"key":"97_CR87","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.1038\/s41598-024-57597-8","volume":"14","author":"M Hinnu","year":"2024","unstructured":"Hinnu, M., Putrin\u0161, M., Kogermann, K., Kaldalu, N. & Tenson, T. Fluorescent reporters give new insights into antibiotics-induced nonsense and frameshift mistranslation. Sci. Rep. 14, 6883 (2024).","journal-title":"Sci. Rep."},{"key":"97_CR88","doi-asserted-by":"publisher","first-page":"111173","DOI":"10.1016\/j.celrep.2022.111173","volume":"40","author":"L Tadala","year":"2022","unstructured":"Tadala, L. et al. Infection-induced membrane ruffling initiates danger and immune signaling via the mechanosensor PIEZO1. Cell Rep 40, 111173 (2022).","journal-title":"Cell Rep"},{"key":"97_CR89","doi-asserted-by":"publisher","first-page":"e0104522","DOI":"10.1128\/msystems.01045-22","volume":"8","author":"A Sharma","year":"2023","unstructured":"Sharma, A., Omer Aden, R., Puhar, A. & Cisneros, D. A. CRISPR-Cas-guided mutagenesis of chromosome and virulence plasmid in Shigella flexneri by cytosine base editing. mSystems 8, e0104522 (2023).","journal-title":"mSystems"},{"key":"97_CR90","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1128\/iai.55.11.2681-2688.1987","volume":"55","author":"P Clerc","year":"1987","unstructured":"Clerc, P. & Sansonetti, P. J. Entry of Shigella flexneri into HeLa cells: evidence for directed phagocytosis involving actin polymerization and myosin accumulation. Infect. Immun. 55, 2681 (1987).","journal-title":"Infect. Immun."},{"key":"97_CR91","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1128\/iai.46.1.251-259.1984","volume":"46","author":"AF Labigne-Roussel","year":"1984","unstructured":"Labigne-Roussel, A. F., Lark, D., Schoolnik, G. & Falkow, S. Cloning and expression of an afimbrial adhesin (AFA-I) responsible for P blood group-independent, mannose-resistant hemagglutination from a pyelonephritic Escherichia coli strain. Infect. Immun. 46, 251\u2013259 (1984).","journal-title":"Infect. Immun."},{"key":"97_CR92","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/cyto.a.20864","volume":"77","author":"ML Clarke","year":"2010","unstructured":"Clarke, M. L. et al. Low-cost, high-throughput, automated counting of bacterial colonies. Cytometry Part A 77, 790\u2013797 (2010).","journal-title":"Cytometry Part A"},{"key":"97_CR93","doi-asserted-by":"publisher","first-page":"D1373","DOI":"10.1093\/nar\/gkac956","volume":"51","author":"S Kim","year":"2023","unstructured":"Kim, S. et al. PubChem 2023 update. Nucleic Acids Res. 51, D1373\u2013D1380 (2023).","journal-title":"Nucleic Acids Res."}],"container-title":["npj Antimicrobials and Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44259-025-00097-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44259-025-00097-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44259-025-00097-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T12:03:23Z","timestamp":1744373003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44259-025-00097-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["97"],"URL":"https:\/\/doi.org\/10.1038\/s44259-025-00097-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.11.06.622235","asserted-by":"object"}]},"ISSN":["2731-8745"],"issn-type":[{"value":"2731-8745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}